SUMMARY Fluctuations of mood and psychic activation were assessed in relation to "mobile" and "immobile" periods in 18 patients with Parkinson's disease presenting typical "end-of-dose deterioration". Twelve subjects with chronic but active rheumatoid arthritis presenting increased physical disability due to severe morning joint stiffness with a repetitive pattern of mobile and immobile periods acted as controls. The overall degree of disability and its fluctuations were close enough in the two groups for fair comparison of changes in affective behaviour. Temporary immobility was accompanied by adverse changes of mood and activation, which were significantly more marked in the Parkinson's disease group than in the controls, though to a lesser extent in those Parkinson's disease patients rated depressed even in their mobile periods. The possible correlation between mood changes and fluctuations of central dopaminergic function in the Parkinson's disease patients is discussed.
Together with its clinical relevance to disability,1 -3 one of the most interesting aspects of depression in Parkinson's disease is the problem of its pathogenetic and pathophysiological mechanisms. There is no definite evidence for a "reactive" or for a "primary" genesis of Parkinson's disease depression. Obviously it could be conceived as a psychological reaction to long-lasting motor impairment and yet it often precedes the onset of motor impairment,3 and depression is reportedly more common among Parkinsonians than among patients with other, equally severe, chronic diseases.4 This being so, some authors have been tempted to attribute Parkinson's disease depression to the pathobiology of the disease itself. [4] [5] [6] [7] Some have attributed a pathophysiological role in Parkinson's disease mood disturbances to impairment of the mesocortical and mesolimbic dopaminergic pathways.5 6 These structures, which degenerate in many Parkinson's disease patients,8 9 have been shown to play a crucial role in the psychophysiological reinforcement/reward processes 6 which, in turn, are likely to be involved in the pathophysiology of "primary" or "endogenous" or "endo-genomorphic"10 depression. Hence the suggested correlation between Parkinson's disease depression and impaired function of the mesocortical and mesolimbic dopamine systems.5 6 However, this fascinating hypothesis raises two more basic questions: can we adduce further data to prove the reactive or primary nature of Parkinson's disease depression? And can we establish any correlation between mood disturbances and central dopaminergic activity in Parkinson's disease? The on-off phenomenon in Parkinson's disease may provide relevant information. During motor swings the striatal dopaminergic function fluctuates "from one extreme to the other"' 1 and it has been assumed that such changes occur-;n the other dopamine systems as well.'' 12 Fluctuations may perhaps occur in non-motor aspects of Parkinson's disease, if these aspects are dependent upon the functional integrity of dopamine systems. " 12 On this assumption, the on-off paradigm was used to investigate the possible relationship of cognitive function" 1' and nociception'2 to central dopaminergic activity in Parkinson's disease. Brown etal" have also focused on the "affect-arousal state" of swinging Parkinsonians, and found the "off"' period to be accompanied by a definite worsening of this index. The association between on-off motor changes and mood swings was then strikingly pointed out by Hardie et al. "4 Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study focal signs of organic brain damage. During both their "mobile" and "immobile" periods the score on the Minimental state16 was above 24 in all subjects. Two controls had been taking psychotropic drugs, but these were stopped a month prior to examination. Anti-inflammatories were the only drugs allowed.
Assessment of disability and of affective behaviour Both Parkinson's disease patients and controls were rated on the scales described below by the same examiner (RC) on two occasions: once during a period of "mobility" (defined as the period in which the patients achieved their lowest score on the disability rating), and once during a period of "immobility" (the highest degree of disability resulting from EDD or from articular stiffness). This two-phase assessment was repeated I week later, with its sequence (mobile/immobile or immobile/mobile) reversed for both groups. Each subject was then assessed four times (twice mobile and twice immobile). The mean values were calculated for each phase. Care was taken to ensure that all the subjects were tested in identical enviromental conditions. All the controls were examined at 7 am (immobile period) and at 11 am (mobile period), which corresponded to the repetitive pattern of their articular stiffness. After a prolonged clinical observation, which enabled us to define the time pattern of their motor fluctuations, 12 out of the 18 Parkinson's disease patients were examined once at 9.30 am (mobile period) and again at 12 noon (immobile period preceding the next levodopa dose). In the remaining six Parkinson's disease subjects the motor pattern was less regular. Disability The test used was the North Western University Disability Scale (NUDS),21 which rates hygiene, eating, dressing, gait and speech on a 0-10 scale. The maximum score was 50 points.
Affective behaviour To obtain a reliable assessment of the behavioural manifestations of depression we used an Italian translation of the Beck Depression Inventory (BDI).22 BDI has often been used to study mood in Parkinson's disease patients' 2 23 24 and it was considered to provide a good index at least for comparative purposes.24 As previously done,2 we gave a zero rating to items "N" (body image), "O" (work inhibition), "Q" (fatiguability) and "T" (somatic preoccupation), as they would presumably be influenced by the increase in physical disability typical of the immobile period rather than by real mood changes. Since the assessment was repeated over very short intervals of time, a zero rating was given to item "S" (loss of weight 
Results
The numerical values are given in tables 2 and 3.
As far as the test-retest reliability of the measures adopted is concerned, the correlations (Spearman Rank correlation test) between the scores obtained in the two immobile periods were the following: Obviously, the NUDS items were differently affected mobile period (tables 2 and 3), 7/18 (38 8%) of Parkinson's disease patients and 3/12 (25%) of controls scored above 10 points on the sBDI. According to Schwab etal, 28 this fits the diagnosis of depression. Moreover, the seven Parkinson's disease patients scoring highly on the sBDI met the DSM III criteria27 for a "major depression". They had reportedly been showing signs and symptoms of depression for several years (mean + SD = 7 9 + 4 1); in three of them the onset of depression was described as nearly coinciding with the onset of Parkinson's disease motor disturbances, while in the remaining four depression had antedated the cardinal features of Parkinson's dis- AES scores significantly lower than those of "non-steadily depressed" PD patients (nPD) (p < 005; p < 0 01). This phenomenon is not observed among "steadily depressed" and "non-steadily depressed" Controls (dC and nC respectively). Bars represent SD.
ease. On this basis, we rated these seven patients as "steadily depressed" Parkinsonians (dPD). They differed in affective behaviour during the immobile period from the remaining "non-steadily depressed" Parkinson's disease patients (nPD). Figure 4 shows that the (immobile-mobile) mean value on the sBDI in dPD is significantly lower than the corresponding value in nPD (p < 0-05, Wilcoxon Rank Sum test). This difference was not observed between steadily depressed and non-steadily depressed controls, similarly defined (fig4). (It must be emphasised that the three controls scoring highly on the sBDI in their mobile period met the DSM III diagnostic criteria27 for a "dysthymic disorder"). group.bmj.com on October 9, 2016 -Published by http://jnnp.bmj.com/ Downloaded from Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study Mean AES values and their changes in Parkinson's disease patients and controls are shown in fig 3. Mean mobile AES values do not significantly differ in the two groups. By contrast, during the immobile period there is a decrease in the AES score that appears to be much greater in Parkinson's disease patients than in controls (p < 0-001). The AES decrease during the immobile period is significant both within the Parkinson's disease and within the control group (p < 0-01 and < 0-05 respectively). dPD patients show a smaller decrease in their AES score during the immobile period than nPD patients (p < 0.01) (fig4). This difference is absent in the control group (fig 4) . Mini-mental state In both groups values obtained during the mobile period do not differ significantly from the corresponding values in the immobile period. Correlations (tables 4 and 5). During both the mobile and the immobile period, a significant (p < 0-05) correlation was found in the control, but not in the Parkinson's disease group, between sBDI/AES scores and duration of illness. In Parkinson's disease patients, but not in controls, there was a significant (p < 0.05) correlation between NUDS and sBDI/AES scores in the mobile period. If the change in the measures during the immobile period is considered (immobile-mobile values), the increase in the NUDS scores does not correlate with that in the sBDI/AES scores among Parkinson's disease patients. There is a tendency to such a correlation among controls, but it does not attain statistical significance. sBDI and AES scores in the mobile period and their changes in the immobile period show a strong (p < 0-01) correlation in the Parkinson's disease but not in the control group.
Discussion
Several methodological problems had to be solved in the course of our study of the affective changes attending end-of-dose deterioration in long-term levodopa treated Parkinson's disease patients. Careful selection of Parkinson's disease subjects was essential in order to exclude non-idiopathic cases: any conclusion drawn from studies including (for instance) atherosclerotic or toxic Parkinsonism cases would be misleading. The fluctuations in motor function had to have all the characters typical of end-ofdose deterioration, as described by Marsden and Parkes"7 for any proper assessment of affective behaviour during a period of central dopaminergic deficiency. We further had to exclude subjects presenting with signs of intellectual impairment, as detected by the Mini-mental state.'6 Consequently, the number of Parkinson's disease patients acceptable for the study was fairly small. Selection of controls was equally strict. Reliable and simple instruments for assessing affective behaviour were required, since akinesia and other Parkinson's disease motor or sensory symtoms, exacerbated during end-of-dose deterioration, would distort several of the items belonging to the common scales used to rate depression. Although possible contamination of this kind could perhaps be tolerated in our experimental situation, where equally disabled groups were compared, we tried to keep it to a minimum by using the sBDI and the AES (see Method). The use of a control group consisting of subjects prone to intermittent physical disability (unrelated to CNS alterations) allowed us to discriminate the merely "reactive" depressive changes that might accompany "immobile" periods. Obviously, the increasing motor impairment and the general discomfort typical of end-of-dose deterioration can be expected to produce temporary adverse mood changes, as a result of a "psychological reaction". This important factor cannot be taken into account if normal subjects are selected as controls. Depression is common among subjects suffering from chronic rheumatic diseases, but is thought to be a "psychological reaction" to pain and gradually declining function.29 This being so, we expected a comparative study of affective behaviour in Parkinson's disease and rheumatoid arthritis patients to highlight the "neurobiological" substrates of Parkinson's disease depression. Although the two groups were evaluated on the Mini-mental state16 both in the mobile and the immobile period (without finding any significant difference), we did not make a comprehensive assessment of their intellectual function. In our preliminary study,2 concomitant evaluation of mood and cognitive performance proved to be difficult: patients unduly burdened with questions and tests seemed to be less cooperative and reliable. Besides, Brown et al1 stressed that adverse changes in mood and alertness tended to trigger the functional cognitive impairment which characterised a proportion of their "off" Parkinson's disease patients. Thus, we thought it was justified to study mood and activation changes in their own right; moreover, it seemed unlikely that subtle and inconstant cognitive changes could affect the simple self-rating scales we used.
Our results showed that the overall physical disability was similar in the Parkinson's disease and the control group, both in the mobile and the immobile period. Thus, the most important condition for a correct comparison was fulfilled. Thus, as far as group results are concerned, two main points arise: (1) In the mobile period signs and symptoms of depression were present both among Parkinson's disease patients and controls. However, they were significantly more common in the former group, a finding that confirms those of Robins.4 Assuming that the adverse mood changes in the control group were an example of steady "psychological reaction" to chronic disability, the higher incidence of depression in the Parkinson's disease group may indicate further depressive mechanisms, perhaps related to the pathobiology of Parkinson's disease. This is indirectly supported by the different clinical features of depression in the two groups, as evaluated on the DSM III criteria.27 (2) During the immobile period, that is during the temporary increase in disability, a worsening of mood and, even more, of self-rated psychic activation was found both in the Parkinson's disease and in the control groups. However, it was significantly greater among Parkinson's disease patients. It must be remembered that adverse changes in the "affect/arousal state" were described by Brown etal If individual results are considered, it is evident that the reversible increase in disability typical of the immobile period was associated with a less severe worsening of mood and psychic activation in "steadily depressed" than in "non-steadily depressed" Parkinson's disease subjects, a finding that was not seen among controls. There are two possible explanations for this phenomenon: (a) "steady depression" in ourability and the change in the depressive scores during immobility, whereas such a trend was revealed in the controls, although it was not statistically significant.
In no case did we observe very dramatic, cyclical swings in mood of Parkinson's disease patients resembling those of the hypomanic-depressive illness and paralleling the "on" and the "of' periods. In every instance adverse mood changes in the Parkinson's disease group were accompanied by a significant worsening of self-rated psychic activation, as evaluated by the AES. In those subjects in whom mood did not change, psychic activation did not change. Classically, levodopa is thought to exert a general "arousing" influence on Parkinson's disease subjects, so that lower levels of alertness, at least as subjectively appreciated, seem to be an obvious finding during end-ofdose deterioration, a condition associated with low or falling plasma levodopa levels. 17 -19 Besides, the close parallelism of mood and activation features in our Parkinson's disease patients led us to speculate that these two altered aspects of psychic function may have some common anatomophysiological impairment, related to CNS dopaminergic mechanisms.
Altered dopamine metabolism has been reported in subgroups of patients affected by retarded depression, even without Parkinson's disease. 32 The effect of tricylic antidepressants, which can relieve Parkinson's disease depression,3 may be mediated by interaction with dopaminergic neurotransmission.33 Moreover, Mayeux etal34 found homovanillic acid levels lower in the CSF of Parkinson's disease patients with a "major depression" than in the others. Although these authors did not comment on this feature of their results, it might suggest that a severe, widespread derangement of dopamine metabolism, resulting from the combined failure of nigro-and non-nigrostriatal dopamine systems, may underlie or predispose to major depression in Parkinson's disease. However, this interpretation was later challenged by the authors themselves, who stressed the importance of abnormal serotonin metabolism in depressed Parkinsonians.
In our opinion, the interactions between the neurotransmitter and neuromodulator systems damaged in Parkinson's disease are too complex for depression to be ascribed to one or other of the neural structures. In any case, our study does not provide conclusive evidence to exclude the "reactive" process as a causal factor of Parkinson's disease depression. However, the higher overall level of depression in the Parkinson's disease group, their more adverse mood changes accompanying increased disability and the peculiarities of affective behaviour within the group itself showed that a "reactive" model is not sufficient to explain their depression. We are inclined to think that biological mechanisms were also at work, and that central dopaminergic deficiency probably played a predisposing or contributory role.
Preliminary results of this study were presented at the First Meeting of the Italian Society of Neurosciences (Rome, 12-15 Dec, 1984) .
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